Thursday, June 14, 2018

Benchling Gets $14.5M For Life Science Collaboration

San Francisco-based Benchling, a developer of data management and collaboration tools for life sciences research, has raised $14.5M in a Series B funding, the company said this morning. The funding was led by Benchmark, and also included F-Prime Capital (the VC firm associated with Fidelity Investments), along with Thrive Capital. Eric Vishria of Benchmark joins the comany's board with the funding. Benchling said that such biotech and pharmaceuticals companies as Regeneron Pharmaceuticals, Incyte, Editas Medicine, Agenus, Zymergen, and Obsidian Therapeutics are using its software. More information »